Actym Therapeutics, a US-based company that deals with drug modality to treat solid tumours, announced on Thursday that it has named Steven Vicik, PhD, as its new chief technical officer (CTO).

In the new role, Vicik is to head and implement the company's technology strategy and advance its proprietary platform, S. Typhimurium-Attenuated Cancer Therapy (STACT).

Dr Vicik has more than 25 years of experience in pharmaceutical process and product development, manufacturing operations, and supply chain design and distribution for large and small molecule drugs. He has served as CTO at Xalud Therapeutics, various leadership roles at Pfizer, Wyeth, and Genetics Institute. He is the holder of various large molecule manufacturing patents.